You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting
|
|---|---|
| Published in |
Frontiers in Pharmacology, April 2014
|
| DOI | 10.3389/fphar.2014.00055 |
| Pubmed ID | |
| Authors |
María A. Antor, Alberto A. Uribe, Natali Erminy-Falcon, Joseph G. Werner, Keith A. Candiotti, Joseph V. Pergolizzi, Sergio D. Bergese |
| Abstract |
Postoperative nausea and vomiting (PONV) is one of the most common and undesirable complaints recorded in as many as 70-80% of high-risk surgical patients. The current prophylactic therapy recommendations for PONV management stated in the Society of Ambulatory Anesthesia (SAMBA) guidelines should start with monotherapy and patients at moderate to high risk, a combination of antiemetic medication should be considered. Consequently, if rescue medication is required, the antiemetic drug chosen should be from a different therapeutic class and administration mode than the drug used for prophylaxis. The guidelines restrict the use of dexamethasone, transdermal scopolamine, aprepitant, and palonosetron as rescue medication 6 h after surgery. In an effort to find a safer and reliable therapy for PONV, new drugs with antiemetic properties and minimal side effects are needed, and scopolamine may be considered an effective alternative. Scopolamine is a belladonna alkaloid, α-(hydroxymethyl) benzene acetic acid 9-methyl-3-oxa-9-azatricyclo non-7-yl ester, acting as a non-selective muscarinic antagonist and producing both peripheral antimuscarinic and central sedative, antiemetic, and amnestic effects. The empirical formula is C17H21NO4 and its structural formula is a tertiary amine L-(2)-scopolamine (tropic acid ester with scopine; MW = 303.4). Scopolamine became the first drug commercially available as a transdermal therapeutic system used for extended continuous drug delivery during 72 h. Clinical trials with transdermal scopolamine have consistently demonstrated its safety and efficacy in PONV. Thus, scopolamine is a promising candidate for the management of PONV in adults as a first line monotherapy or in combination with other drugs. In addition, transdermal scopolamine might be helpful in preventing postoperative discharge nausea and vomiting owing to its long-lasting clinical effects. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 1% |
| Unknown | 67 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 13% |
| Student > Master | 9 | 13% |
| Student > Bachelor | 8 | 12% |
| Researcher | 7 | 10% |
| Student > Doctoral Student | 5 | 7% |
| Other | 19 | 28% |
| Unknown | 11 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 13% |
| Biochemistry, Genetics and Molecular Biology | 7 | 10% |
| Agricultural and Biological Sciences | 6 | 9% |
| Neuroscience | 3 | 4% |
| Other | 10 | 15% |
| Unknown | 17 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2024.
All research outputs
#19,913,054
of 25,342,911 outputs
Outputs from Frontiers in Pharmacology
#8,423
of 19,566 outputs
Outputs of similar age
#164,802
of 235,046 outputs
Outputs of similar age from Frontiers in Pharmacology
#38
of 76 outputs
Altmetric has tracked 25,342,911 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 19,566 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,046 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.